Standout Papers

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcome... 2019 2026 2021 2023 532
  1. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial (2019)
    Anders Widmark, Adalsteinn Gunnlaugsson et al. The Lancet

Immediate Impact

1 from Science/Nature 57 standout
Sub-graph 1 of 23

Citing Papers

Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer
2023 Standout
Recent advances on modulation of H2O2 in tumor microenvironment for enhanced cancer therapeutic efficacy
2023 Standout
1 intermediate paper

Works of Måns Agrup being referenced

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
2019 Standout

Author Peers

Author Last Decade Papers Cites
Måns Agrup 560 13 4 411 181 14 722
Alessandro Magli 546 79 25 329 225 33 735
Peter-Paul van der Toorn 444 25 359 160 14 612
Magnus Lagerlund 592 3 2 446 178 10 810
Huong Pham 421 81 20 327 129 31 592
Ruth Peter 438 4 4 338 184 11 620
Steve Leibel 528 147 33 282 177 10 690
Edward Soffen 449 26 14 334 141 17 607
Mark L. Sobczak 470 9 37 416 253 23 793
David L. Andolino 383 11 19 355 190 7 656
Raxa Sankreacha 401 1 463 165 26 686

All Works

Loading papers...

Rankless by CCL
2026